Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis

被引:58
作者
Atkins, GJ
Bouralexis, S
Evdokiou, A
Hay, S
Labrinidis, A
Zannettino, ACW
Haynes, DR
Findlay, DM
机构
[1] Univ Adelaide, Dept Orthopaed & Trauma, Adelaide, SA 5000, Australia
[2] Royal Adelaide Hosp, Adelaide, SA 5000, Australia
[3] Univ Adelaide, Inst Med & Vet Sci, Div Haematol, Adelaide, SA 5000, Australia
[4] Univ Adelaide, Dept Pathol, Adelaide, SA 5000, Australia
基金
英国医学研究理事会;
关键词
human osteoblasts; Apo2L/TRAIL; receptors; apoptosis; caspase; chemotherapy;
D O I
10.1016/S8756-3282(02)00858-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Apo2 ligand (Apo2L/TRAIL) is a member of the tumor necrosis factor (TNF) cytokine family. Apo2L/TRAIL can selectively induce programmed cell death in transformed cells, although its wide tissue distribution suggests potential physiological roles. We have investigated the expression, in human osteoblast-like cells (NHBC), of Apo2L/TRAIL and the known Apo2L/TRAIL death receptors, DR4 and DR5, and the Apo2L/TRAIL decoy receptors, DcR-1, DcR-2, and osteoprotegerin (OPG). NHBC expressed abundant mRNA corresponding to each of these molecular species. Immunofluorescence staining demonstrated that Apo2L/TRAIL protein was abundant within the cytoplasm of NHBC and OPG was strongly expressed at the cell surface. DR5 and DcR-2 were present in the cell membrane and cytoplasm and DcR-1 was confined to the nucleus. DR4 staining was weak. Neither Apo2L/TRAIL alone, nor in combination with chemotherapeutic agents of clinical relevance to treatment of osteogenic sarcoma, induced cell death in NRBC, as assessed morphologically and by activation of caspase-3. In contrast, the human osteogenic sarcoma cell lines, BTK-143 and G-292, were sensitive to exogenous Apo2L/TRAIL alone, and to the combined effect of Apo2L/TRAIL/cisplatin and Apo2L/TRAIL/doxorubicin treatments, respectively. In NHBC, we observed strong associations between the levels of mRNA corresponding to the pro-apoptotic molecules, Apo2L/TRAIL, DR4, and DR5, and those corresponding to prosurvival molecules, DcR-1, DcR-2, OPG, and FLIP, suggesting that the balance between pro-survival and pro-apoptotic molecules is a mechanism by which NHBC can resist Apo2L/TRAIL-mediated apoptosis. In contrast, osteogenic sarcoma cells had low or absent levels of DcR-1 and DcR-2. These results provide a foundation to explore the role of Apo2L/TRAIL in osteoblast physiology. In addition, they predict that therapeutic use of recombinant Apo2L/TRAIL, in combination with chemotherapeutic agents to treat skeletal malignancies, would have limited toxic effects on normal osteoblastic cells.
引用
收藏
页码:448 / 456
页数:9
相关论文
共 44 条
  • [21] Ceramide-induced nuclear translocation of NF-kappa B is a potential mediator of the apoptotic response to TNF-alpha in murine clonal osteoblasts
    Kitajima, I
    Soejima, Y
    Takasaki, I
    Beppu, H
    Tokioka, T
    Maruyama, I
    [J]. BONE, 1996, 19 (03) : 263 - 270
  • [22] Increased cyclooxygenase-2 (cox-2) expression and activity in a murine model of metastatic breast cancer
    Kundu, N
    Yang, QY
    Dorsey, R
    Fulton, AM
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2001, 93 (05) : 681 - 686
  • [23] Lacour S, 2001, CANCER RES, V61, P1645
  • [24] Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
    Lawrence, D
    Shahrokh, Z
    Marsters, S
    Achilles, K
    Shih, D
    Mounho, B
    Hillan, K
    Totpal, K
    DeForge, L
    Schow, P
    Hooley, J
    Sherwood, S
    Pai, R
    Leung, S
    Khan, LL
    Gliniak, B
    Bussiere, J
    Smith, CA
    Strom, SS
    Kelley, S
    Fox, JA
    Thomas, D
    Ashkenazi, A
    [J]. NATURE MEDICINE, 2001, 7 (04) : 383 - 385
  • [25] A novel receptor for Apo2L/TRAIL contains a truncated death domain
    Marsters, SA
    Sheridan, JP
    Pitti, RM
    Huang, A
    Skubatch, M
    Baldwin, D
    Yuan, J
    Gurney, A
    Goddard, AD
    Godowski, P
    Ashkenazi, A
    [J]. CURRENT BIOLOGY, 1997, 7 (12) : 1003 - 1006
  • [26] Marsters SA, 1999, RECENT PROG HORM RES, V54, P225
  • [27] Medina V, 1997, CANCER RES, V57, P3697
  • [28] Nagane M, 2000, CANCER RES, V60, P847
  • [29] Elevated Akt activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis
    Nesterov, A
    Lu, XJ
    Johnson, M
    Miller, GJ
    Ivashchenko, Y
    Kraft, AS
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (14) : 10767 - 10774
  • [30] An antagonist decoy receptor and a death domain-containing receptor for TRAIL
    Pan, GH
    Ni, J
    Wei, YF
    Yu, GL
    Gentz, R
    Dixit, VM
    [J]. SCIENCE, 1997, 277 (5327) : 815 - 818